BRPI0509894A - composições farmacêuticas compreendendo um amido anfifìlico - Google Patents

composições farmacêuticas compreendendo um amido anfifìlico

Info

Publication number
BRPI0509894A
BRPI0509894A BRPI0509894-7A BRPI0509894A BRPI0509894A BR PI0509894 A BRPI0509894 A BR PI0509894A BR PI0509894 A BRPI0509894 A BR PI0509894A BR PI0509894 A BRPI0509894 A BR PI0509894A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
starch
compositions
excipients
amphiphilic starch
Prior art date
Application number
BRPI0509894-7A
Other languages
English (en)
Inventor
John Staniforth
Naresh Talwar
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of BRPI0509894A publication Critical patent/BRPI0509894A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIçõES FARMACêUTICAS COMPREENDENDO UM AMIDO ANFIFìLICO. A presente invenção refere-se a liberação controlada ou sustentada de composições farmacêuticas sólidas, a excipientes farmacêuticos para uso na fabricação de tais composições e a processos de produção de tais composições e excipientes. Os excipientes de liberação controlada ou sustentada incluem um excipiente de controle de liberação contendo um amido anfifílico.
BRPI0509894-7A 2004-04-14 2005-04-14 composições farmacêuticas compreendendo um amido anfifìlico BRPI0509894A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0408308.5A GB0408308D0 (en) 2004-04-14 2004-04-14 Pharmaceutical compositions
PCT/GB2005/050051 WO2005099674A1 (en) 2004-04-14 2005-04-14 Pharmaceutical compositions comprising an amphiphilic starch

Publications (1)

Publication Number Publication Date
BRPI0509894A true BRPI0509894A (pt) 2007-10-30

Family

ID=32320811

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509894-7A BRPI0509894A (pt) 2004-04-14 2005-04-14 composições farmacêuticas compreendendo um amido anfifìlico

Country Status (15)

Country Link
US (1) US20080171083A1 (pt)
EP (1) EP1734932A1 (pt)
JP (1) JP2007532620A (pt)
KR (1) KR20070053163A (pt)
CN (1) CN1968683A (pt)
AU (1) AU2005232442A1 (pt)
BR (1) BRPI0509894A (pt)
CA (1) CA2562806A1 (pt)
GB (1) GB0408308D0 (pt)
IL (1) IL178611A0 (pt)
MX (1) MXPA06011860A (pt)
NO (1) NO20065190L (pt)
NZ (1) NZ550648A (pt)
SG (1) SG152240A1 (pt)
WO (1) WO2005099674A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU764453B2 (en) 1999-10-29 2003-08-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
AU2003207291A1 (en) * 2002-02-06 2003-09-02 Ube Industries, Ltd. Process for producing 4-aminoquinazoline compound
WO2004112756A1 (en) 2003-06-26 2004-12-29 Isa Odidi Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US7993678B2 (en) * 2005-09-26 2011-08-09 Novozymes Biopolymer A/S Hyaluronic acid derivatives
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA2648280C (en) 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
NZ703464A (en) * 2006-04-26 2016-05-27 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
ES2288117B1 (es) * 2006-05-08 2008-12-01 Combino Pharm, S.L. Composicion farmaceutica solida de gabapentina.
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
EA201000585A1 (ru) * 2007-10-05 2010-10-29 КРКА, д.д., НОВО МЕСТО Многочастичная матричная система, содержащая галантамин
EP2044933A1 (en) * 2007-10-05 2009-04-08 KRKA, D.D., Novo Mesto Multi particulate matrix system containing galantamine
BRPI0920895A8 (pt) 2008-10-07 2017-12-26 Actelion Pharmaceuticals Ltd Compostos antibióticos de oxazolidinona tricíclica
WO2010092260A2 (fr) * 2009-02-13 2010-08-19 Ipsen Pharma S.A.S. Compositions pharmaceutiques du 6-oxo-6.7.8,9.10.11-hexahydrocyclohepta mchromen-3-yl sulfamate
US20100215758A1 (en) * 2009-02-25 2010-08-26 Joar Opheim Effervescent nutritional and/or dietary supplement composition
CA2798702A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholresistant metoprolol-containing extended-release oral dosage forms
JP5656258B2 (ja) * 2011-03-09 2015-01-21 塩野義製薬株式会社 ガランタミンを含有する口腔内崩壊錠剤
WO2013077847A1 (en) * 2011-11-21 2013-05-30 Handa Pharmaceuticals, Llc Oral dosage forms for delivering gabapentin
WO2013183422A1 (ja) * 2012-06-08 2013-12-12 理研ビタミン株式会社 ステアロイル乳酸ナトリウム製剤
EP2906202A4 (en) * 2012-10-15 2016-04-27 Isa Odidi ORAL DRUG RELIEF FORMULATIONS
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10694778B2 (en) 2013-12-31 2020-06-30 Philip Morris Products S.A. Smoking article with liquid delivery material
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN110251686B (zh) * 2019-06-28 2021-02-19 华南理工大学 一种淀粉基两亲性自组装载体材料及其制备方法与应用
EP3818975A1 (en) * 2019-11-08 2021-05-12 Roquette Freres Use of sodium octenyl-succinate starches as a binder in continuous wet granulation
EP3819336A1 (en) * 2019-11-08 2021-05-12 Roquette Freres Use of octenyl-succinate starches as a binder in wet granulation
US20240209122A1 (en) * 2021-04-01 2024-06-27 Guantian LI Nonenyl succinic anhydride modified starch, preparation method therefor, and application thereof
WO2026004959A1 (ja) * 2024-06-27 2026-01-02 株式会社カネカ コエンザイムｑ１０含有組成物、コエンザイムｑ１０の吸収促進剤及び吸収促進方法、並びにコエンザイムｑ１０の徐放性向上剤及び徐放性向上方法
CN120093706B (zh) * 2025-05-09 2025-09-09 江苏安必生制药有限公司 一种美沙拉秦肠溶缓释片剂及其制备工艺

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1405088A (en) 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
EP0147780A3 (en) 1984-01-03 1987-03-11 Merck & Co. Inc. Drug delivery device
ATE61935T1 (de) 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
JP3114758B2 (ja) * 1991-02-13 2000-12-04 東ソー株式会社 ポリフェニレンスルフィド樹脂組成物
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
BE1009380A3 (nl) * 1995-03-14 1997-03-04 Universiteit Gent Lab Voor Far Stabiliserend samenstelling voor suspensie.
DE19619837B4 (de) * 1996-05-17 2007-03-08 Beiersdorf Ag Kosmetische oder pharmazeutische Zubereitungen mit vermindertem Klebrigkeitsgefühl
JP4028642B2 (ja) * 1997-10-07 2007-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳化粉末の製造方法
EP0972513B1 (en) * 1997-10-07 2003-05-02 Eisai Co., Ltd. Process for preparing emulsified powder
AU736348B2 (en) * 1997-10-31 2001-07-26 Corn Products Development, Inc. Use of an enzymatically-converted starch derivative as an encapsulating agent
EE04996B1 (et) * 1998-12-24 2008-04-15 Janssen Pharmaceutica N.V. Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend
DE10135694A1 (de) * 2001-07-21 2003-02-06 Supramol Parenteral Colloids Amphiphile Stärke-und Hydroxyethylstärke-Konjugate
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
MXPA02011337A (es) * 2001-11-16 2003-05-26 Nat Starch Chem Invest Peliculas que contienen almidon.
US20050158380A1 (en) * 2002-06-07 2005-07-21 Manish Chawla Sustained release oral dosage forms of gabapentin
US8252322B2 (en) * 2003-06-03 2012-08-28 Corn Products Development, Inc. Delivery system with increased bioavailability
CN1270717C (zh) * 2003-11-28 2006-08-23 李思成 加兰他敏缓释制剂及其制备方法

Also Published As

Publication number Publication date
EP1734932A1 (en) 2006-12-27
IL178611A0 (en) 2007-02-11
WO2005099674A1 (en) 2005-10-27
NO20065190L (no) 2007-01-11
GB0408308D0 (en) 2004-05-19
SG152240A1 (en) 2009-05-29
AU2005232442A1 (en) 2005-10-27
JP2007532620A (ja) 2007-11-15
NZ550648A (en) 2009-09-25
MXPA06011860A (es) 2007-01-25
US20080171083A1 (en) 2008-07-17
CA2562806A1 (en) 2005-10-27
KR20070053163A (ko) 2007-05-23
CN1968683A (zh) 2007-05-23

Similar Documents

Publication Publication Date Title
BRPI0509894A (pt) composições farmacêuticas compreendendo um amido anfifìlico
HN2003000196A (es) Derivados de indolinfenilsulfonamida
CY1122575T1 (el) Φαρμακοτεχνικες μορφες διστρωματικου δισκιου
UY30578A1 (es) Nuevos derivados de 2,4??- y 3, 4??-bipiridina sustituidos, procedimientos para su preparacion, medicamentos conteniéndolos y aplicaciones
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
ECSP077271A (es) Derivados de pirimidina
MXPA05011208A (es) Uso de ivermectina para el tratamiento de desordenes dermatologicos.
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
NO20091299L (no) Substituerte sulfonamidderivater
DK1427708T3 (da) Amino-phthalazinon-derivater som kinase-inhibitorer, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger der indeholder det samme
BRPI0618552B8 (pt) compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos
UY30712A1 (es) Nuevos derivados de 1, 4-benzotiepina-1, 1-dioxido sustituidos con fluor, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.
DOP2002000429A (es) Imidazotriazinas
HRP20090194T1 (hr) Suha granulirana kompozicija koja sadrži emtricitabin i tenofovir df
CY1118180T1 (el) Μεθοδος για παρασκευη στερεας φαρμακευτικης συνθεσης
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
UY27852A1 (es) Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
CL2011003144A1 (es) Forma cristalina e3 de bisulfato de atazanavir; composicion farmaceutica que la comprende; util para el tratamiento de enfermedades originadas por retrovirus (divisional de la solicitud 1057-05).
CY1113482T1 (el) Αναστολεις υποδοχεα σιγμα
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: PHARMAKODEX LIMITED (GB)

Free format text: TRANSFERIDO DE: VECTURA LIMITED

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.